Searchable abstracts of presentations at key conferences in endocrinology

ea0077p72 | Metabolism, Obesity and Diabetes | SFEBES2021

Impact of PCSK9 Inhibitors on hypercholesterolaemic patients at a tertiary centre lipid clinic

Israni Alisha , Jones Ben , Salem Victoria , Bravis Vassiliki

Background: Elevated low-density lipoprotein cholesterol (LDL-C), which arises due to genetic and environmental factors, has a causal role in the pathogenesis of cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are approved for patients with familial hypercholesterolaemia (FH) and patients at high risk of CVD due to non-familial hypercholesterolaemia (non-FH). In clinical trials, PCSK9 inhibitors are well-tolerated and lead to redu...